IP Library Granted Patent US 7,070,813
Granted Patent B2
US 7,070,813 · App. 10/285,334 · Granted Jul 4, 2006

Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,070,813
App. No.
10/285,334
Granted
Jul 4, 2006
Kind
B2
Abstract

The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.

Claims (10)

1. A method for decreasing the proliferation of human colon adenocarcinoma cells, said method comprising:

introducing to said human colon adenocarcinoma cells a composition comprising a processed Morinda citrifolia product present in an amount between about 0.01 and 100 percent by weight of the composition, said processed Morinda citrifolia product comprising the active ingredient Quercetin, wherein said processed Morinda citrifolia product is selected from the group consisting of Morinda citrifolia fruit juice, Morinda citrifolia puree juice, Morinda citrifolia puree, Morinda citrifolia fruit juice concentrate and Morinda citrifolia puree juice concentrate.

2. The method of claim 1 , wherein said Quercetin is present in an amount between about 0.1 and 10 percent by weight.

3. The method of claim 1 , wherein said processed Morinda citrifolia product further comprises Rutin.

4. The method of claim 3 , wherein said Rutin is present in an amount between about 0.1 and 10 percent by weight of the composition.

5. The method of claim 1 , wherein said composition is administered orally.

6. The method of claim 1 , wherein said composition is administered transdermally to said adenocarcinoma cells.

7. The method of claim 1 , wherein said composition is administered by injection into said adenocarcinoma cells.

8. The method of claim 1 , wherein said composition is administered intravenously.

9. The method of claim 1 , wherein said composition is administered systemically.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2007
From: MORINDA, INC.
To: TAHITIAN NONI INTERNATIONAL, INC.
Reel/Frame 018851/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2003
From: JENSEN, CLAUDE JARAKAE; PALU, AFA KEHAATI; STORY, STEPHEN P.; JENSEN, SUMMER; SU, CHEN
To: MORINDA, INC.
Reel/Frame 013752/0709 →